EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 318 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... February 9, 2023 Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced... August 30, 2024 More Immunotherapy Options Approved for Treating Endometrial Cancer August 6, 2024 Study in India Could Make Immunotherapy More Affordable Worldwide November 22, 2022 Load more HOT NEWS 3 ways we’re helping teenagers and young adults with cancer Running a cancer helpline in COVID-19: two years on the virtual... World Cancer Day 2023: where does the UK stand? Lung Cancer Death Rates Among Women in Europe Are Finally Levelling...
